What is the new gene therapy for Sanfilippo syndrome?

We have folded our coverage of this story into one complete guide: Is there really a first FDA-approved treatment for Sanfilippo syndrome?

The short version: Fayuvi, a one-time gene therapy made by Ultragenyx, is the first treatment ever approved for Sanfilippo syndrome type A in children. For the full picture — how the therapy works, what FDA approval actually means, what families usually do next, and what to watch from here — read the complete guide.

Why a first-ever treatment changes things for families

Sanfilippo syndrome type A is a rare condition in children that steadily takes away mental and motor abilities, and until now there has been no approved treatment to offer families. That is why the FDA's full approval of Fayuvi matters beyond one product: it gives doctors and families something real to discuss.

What to do, step by step

1. Start with the complete guide linked above, which pulls our coverage of this approval into one place.
2. Keep the basics straight: Fayuvi is a one-time gene therapy from Ultragenyx, approved for children with type A.
3. Understand that approval means regulators judged it ready for use, not a promise of any outcome.
4. Families usually talk next steps through with their child's own specialist team, who know their case.
5. Follow reputable updates from the FDA and the maker rather than social posts for what happens next.